TORONTO, July 5, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that the U.S. Food and Drug Administration (FDA) has completed its review of the Biohaven's investigational drug application (IND) for BHV-4157 filed on May 31, 2016 and informed Biohaven that clinical trials in humans may proceed. The IND for BHV-4157 includes plans for a pivotal trial in the indication of Spinocerebellar Ataxia (SCA), a rare and debilitating neurodegenerative disorder with no currently approved treatment. Biohaven plans to initiate a pivotal Phase III clinical trial in SCA before the end of the year.
Toronto May 9, 2016 – Portage Biotech inc (PTGEF) is pleased to announce the appointment of Jim Engelhart, CPA as its Chief Financial Officer. Mr. Engelhart joins Biohaven from Alexion Pharmaceuticals, Inc. (Alexion) where he was an Executive Director providing financial leadership in the North America and Latin America Regions, including financial and commercial support for the launch of two orphan drug indications. Mr. Engelhart has over 17 years of financial leadership experience in global pharmaceutical business units at Bristol-Myers Squibb, Schering-Plough and Alexion.
TORONTO, April 27, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven) has appointed John Tilton as Chief Commercial Officer. Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for four orphan indication launches in over 30 countries for Alexion.